NZ606466A - Peptide radiotracer compositions - Google Patents

Peptide radiotracer compositions

Info

Publication number
NZ606466A
NZ606466A NZ606466A NZ60646611A NZ606466A NZ 606466 A NZ606466 A NZ 606466A NZ 606466 A NZ606466 A NZ 606466A NZ 60646611 A NZ60646611 A NZ 60646611A NZ 606466 A NZ606466 A NZ 606466A
Authority
NZ
New Zealand
Prior art keywords
compositions
imaging
vivo
binding peptides
methods
Prior art date
Application number
NZ606466A
Other languages
English (en)
Inventor
Bhalla Rajiv
Peter Brian Iveson
Bard Indrevoll
Gareth Getvoldsen
Original Assignee
Ge Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ge Healthcare Ltd filed Critical Ge Healthcare Ltd
Publication of NZ606466A publication Critical patent/NZ606466A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nuclear Medicine (AREA)
NZ606466A 2010-08-18 2011-08-11 Peptide radiotracer compositions NZ606466A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1013808.9A GB201013808D0 (en) 2010-08-18 2010-08-18 Peptide radiotracer compositions
PCT/EP2011/063890 WO2012022676A1 (en) 2010-08-18 2011-08-11 Peptide radiotracer compositions

Publications (1)

Publication Number Publication Date
NZ606466A true NZ606466A (en) 2014-11-28

Family

ID=42938098

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ606466A NZ606466A (en) 2010-08-18 2011-08-11 Peptide radiotracer compositions

Country Status (19)

Country Link
US (1) US9533059B2 (enExample)
EP (1) EP2605802B1 (enExample)
JP (1) JP6014592B2 (enExample)
KR (1) KR101853993B1 (enExample)
CN (1) CN103153350B (enExample)
AU (1) AU2011290856B2 (enExample)
BR (1) BR112013003469A2 (enExample)
CA (1) CA2807491C (enExample)
CL (1) CL2013000483A1 (enExample)
ES (1) ES2626410T3 (enExample)
GB (1) GB201013808D0 (enExample)
IL (1) IL224463A (enExample)
MX (1) MX348733B (enExample)
MY (1) MY163136A (enExample)
NZ (1) NZ606466A (enExample)
PH (1) PH12013500270A1 (enExample)
RU (1) RU2594167C2 (enExample)
SG (1) SG187878A1 (enExample)
WO (1) WO2012022676A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201103696D0 (en) * 2011-03-04 2011-04-20 Ge Healthcare Ltd Technetium labelled peptides
GB201121914D0 (en) 2011-12-20 2012-02-01 Ge Healthcare Ltd Method for patient selection
GB201209082D0 (en) * 2012-05-24 2012-07-04 Ge Healthcare Ltd Purification method
GB201221266D0 (en) * 2012-11-27 2013-01-09 Ge Healthcare Ltd Aldehyde compositions
GB201314936D0 (en) 2013-08-21 2013-10-02 Ge Healthcare Ltd Radiolabelling method
GB201322451D0 (en) * 2013-12-18 2014-02-05 Ge Healthcare Ltd Purification method and compositions
GB201322456D0 (en) * 2013-12-18 2014-02-05 Ge Healthcare Ltd Radiotracer compositions and methods
US20190151483A1 (en) * 2016-07-25 2019-05-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Methods of making 18f-labeled precursors and peptides, labeled c-met binding peptides, and methods of use thereof
GB201804835D0 (en) * 2018-03-26 2018-05-09 Ge Healthcare As Formulation and method of preparation
CN114222592A (zh) 2019-06-14 2022-03-22 爱丁堡分子成像有限公司 化合物和使用方法
GB201915206D0 (en) * 2019-10-21 2019-12-04 Ge Healthcare Ltd Use of cyclodextrins as a radiostabilizer
SE2050387A1 (en) * 2020-04-06 2021-10-07 Pvac Medical Tech Ltd Labelled substance and methods of detection of inflammation and infection using said substance
TW202509086A (zh) * 2021-03-22 2025-03-01 日商肽夢想股份有限公司 c－Met蛋白質結合肽複合物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5961955A (en) * 1997-06-03 1999-10-05 Coulter Pharmaceutical, Inc. Radioprotectant for peptides labeled with radioisotope
WO2003057155A2 (en) 2001-12-27 2003-07-17 Van Andel Research Institute Monoclonal antibody imaging and therapy of tumors that express met and bind hepatocyte growth factor
ES2396368T3 (es) * 2003-03-03 2013-02-21 Dyax Corporation Péptidos que se unen específicamente al receptor del HGF (CMET) y usos de los mismos
GB0305704D0 (en) * 2003-03-13 2003-04-16 Amersham Plc Radiofluorination methods
GB0420344D0 (en) * 2004-09-14 2004-10-13 Amersham Plc Diagnostic compounds
US20100068150A1 (en) 2006-07-07 2010-03-18 The Board Of Trustees Of The Leland Stanford Junior University Selective Caspase Inhibitors
GB0615211D0 (en) 2006-07-31 2006-09-06 Ge Healthcare Uk Ltd Asymmetric flouro-substituted polymethine dyes
US8557776B2 (en) 2006-09-08 2013-10-15 Bayer Pharma AG Compounds and methods for 18F labeled agents
WO2008072976A2 (en) 2006-12-13 2008-06-19 Ge Healthcare As Synthesis of a radiofluorinated peptide using microwave activation technology
US8216548B2 (en) * 2006-12-28 2012-07-10 Ge Healthcare As Radiofluorination methods
EA200901142A1 (ru) * 2007-03-01 2010-04-30 Байер Шеринг Фарма Акциенгезельшафт 18f фторбензоильные меченые биологически активные соединения в качестве диагностических визуализирующих средств, а также бензотриазол-1-илоксибензоильные, 2,5-(диоксопирролидин-1-илокси)бензоильные и триметиламмониобензоильные предшественники
CN101848734B (zh) 2007-05-16 2013-08-28 通用电气医疗集团股份有限公司 用于成像的经标记的iigf结合肽
GB0718967D0 (en) * 2007-09-28 2007-11-07 Ge Healthcare Ltd Peptide imaging agents
GB0718957D0 (en) 2007-09-28 2007-11-07 Ge Healthcare Ltd Optical imaging agents
GB0716897D0 (en) 2007-08-30 2007-10-10 Univ Muenchen Tech Cancer imaging and treatment
GB0803477D0 (en) 2008-02-26 2008-04-02 Ge Healthcare As Therapy selection method

Also Published As

Publication number Publication date
PH12013500270A1 (en) 2013-04-01
EP2605802B1 (en) 2017-04-26
US9533059B2 (en) 2017-01-03
CA2807491C (en) 2019-06-04
EP2605802A1 (en) 2013-06-26
MX348733B (es) 2017-06-27
KR20130135242A (ko) 2013-12-10
JP2013540702A (ja) 2013-11-07
US20130149241A1 (en) 2013-06-13
MX2013001939A (es) 2013-03-18
CL2013000483A1 (es) 2014-03-07
WO2012022676A1 (en) 2012-02-23
AU2011290856B2 (en) 2014-12-04
CN103153350A (zh) 2013-06-12
IL224463A (en) 2016-05-31
GB201013808D0 (en) 2010-09-29
BR112013003469A2 (pt) 2016-06-21
JP6014592B2 (ja) 2016-10-25
RU2013105491A (ru) 2014-09-27
CA2807491A1 (en) 2012-02-23
SG187878A1 (en) 2013-03-28
MY163136A (en) 2017-08-15
CN103153350B (zh) 2016-06-29
ES2626410T3 (es) 2017-07-25
AU2011290856A1 (en) 2013-03-14
RU2594167C2 (ru) 2016-08-10
KR101853993B1 (ko) 2018-05-02

Similar Documents

Publication Publication Date Title
NZ606466A (en) Peptide radiotracer compositions
MX2013010012A (es) Analogos de octreotato radiomarcado como trazadores de tomografia por emision de positrones.
UY32037A (es) Daa-piridina
MY150757A (en) Click chemistry-derived cyclopeptide derivatives as imaging agents for integrins
MX2011010295A (es) Reactivos de radiomarcado y metodos.
WO2015073746A3 (en) 18f labeling of proteins using sortases
MX2013012793A (es) Aminoacidos radiomarcados para imagen de diagnostico.
PH12015501092A1 (en) Anti-ceacam5 antibodies and uses thereof
MY188934A (en) Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
EP1919515A4 (en) F-18 PEPTIDES FOR PRECIBLE POSITRON EMISSION TOMOGRAPHY IMAGING
IL201778A0 (en) Peptide imaging agents
EP2928505A4 (en) POSITRONARY EMITTING RADIONUCLEID MARKED PEPTIDES FOR HUMAN UPAR PET IMAGING
GB201103696D0 (en) Technetium labelled peptides
WO2009134405A3 (en) Substrate based pet imaging agents
WO2009018175A3 (en) Cyclic azapeptides as integrin markers
EA201290245A1 (ru) Радиоактивно меченные pde10 лиганды
WO2009025914A3 (en) Radiolabelled fluorobenzamide analogues, their synthesis and use in diagnostic imaging
WO2009013358A3 (en) Polysaccharides grafted by polyamines for the preparation of radiopharmaceutical compositions
PH12013501017A1 (en) Compounds for use in imaging, diagnosing and/or treatment of diseases of the central nervous system
MX2013003398A (es) Agentes de generacion de imagen de apoptosis con base en peptidos lantibioticos.
WO2012040138A3 (en) Choline analogs as radiotracer
WO2011084585A3 (en) Dihydroethidine analogues and uses thereof
BR112013006498A2 (pt) composto
IN2014DN06805A (enExample)
MX340407B (es) Simplificacion de proceso para compuesto precursor.

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 AUG 2016 BY COMPUTER PACKAGES INC

Effective date: 20150718

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 AUG 2017 BY COMPUTER PACKAGES INC

Effective date: 20160719

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 AUG 2018 BY COMPUTER PACKAGES INC

Effective date: 20170718

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 AUG 2019 BY ANAQUA SERVICES

Effective date: 20180719

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 AUG 2020 BY ANAQUA SERVICES

Effective date: 20190722

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 AUG 2021 BY ANAQUA SERVICES

Effective date: 20200721

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 AUG 2022 BY ANAQUA SERVICES

Effective date: 20210720

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 AUG 2023 BY ANAQUA SERVICES

Effective date: 20220721

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 AUG 2024 BY ANAQUA SERVICES

Effective date: 20230720

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 AUG 2025 BY ANAQUA SERVICES

Effective date: 20240723

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 AUG 2026 BY ANAQUA SERVICES

Effective date: 20250723